MarketPulse

Phase 3 trial

33 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Aardvark Therapeutics Stock Plummets 56% as Law Firm Probes Cardiac Safety Concerns

Pomerantz Law Firm investigates Aardvark Therapeutics after Phase 3 trial pause over cardiac safety issues. Stock crashed 56.2% to $5.47.
AARDsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Maia Biotechnology, Inc.

MAIA Biotech Taps Capital Markets for Cancer Drug Development Push

MAIA Biotechnology launches underwritten public offering of common stock and pre-funded warrants to fund clinical trials for its lead cancer therapy ateganosine.
MAIAclinical developmentpublic offering
BenzingaBenzinga··Vandana Singh

United Therapeutics' Ralinepag Shows 55% Drop in PAH Worsening, Stock Soars

United Therapeutics ($UTHR) stock rallies 3.98% after Phase 3 trial shows ralinepag reduces PAH worsening 55%, with FDA filing targeted for mid-2026.
UTHRFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

Bristol Myers' Experimental Breast Cancer Treatment Demonstrates Survival Gains in Advanced Patients

Bristol Myers Squibb's experimental breast cancer drug showed survival improvements in advanced patients, though stock declined slightly following the announcement.
BMYCELGrbreast cancerPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx's VYVGART Meets Primary Endpoint in Ocular Myasthenia Gravis Trial

argenx's VYVGART met its primary endpoint in a Phase 3 ocular myasthenia gravis trial, showing significant symptom improvements. The company plans FDA approval for label expansion.
ARGXFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

Pfizer's Braftovi Combination Therapy Receives Full FDA Approval for BRAF-Mutated Colorectal Cancer

Pfizer's Braftovi receives full FDA approval for treating BRAF-mutated metastatic colorectal cancer when combined with cetuximab and chemotherapy, based on Phase 3 trial data.
PFEFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

FDA Expands Dupixent Approval to Allergic Fungal Rhinosinusitis

FDA approves Dupixent for allergic fungal rhinosinusitis in patients six and older, marking the drug's ninth indication for treating type 2 inflammatory conditions.
SNYREGNFDA approvalPhase 3 trial
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Positioned for Market Expansion as Obesity Drug Sector Scales

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.
LLYNVOVKTXbiotechPhase 3 trial
BenzingaBenzinga··Vandana Singh

Takeda Stock Falls Despite Positive Pediatric UC Data for Entyvio

Takeda stock fell 0.64% despite positive Phase 3 results for Entyvio in pediatric ulcerative colitis, with 47.3% of patients achieving clinical remission.
TAKPhase 3 trialpharmaceutical
BenzingaBenzinga··Vandana Singh

FDA Clears Oral Combination Therapy for Untreated Chronic Lymphocytic Leukemia

FDA approves first all-oral combination therapy for untreated chronic lymphocytic leukemia. The fixed-duration treatment showed 35% reduced progression risk versus chemotherapy.
ABBVRHHBYAZNFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

Eli Lilly's Omvoh Demonstrates Three-Year Remission Durability in Crohn's Disease

Eli Lilly's Omvoh shows durable three-year remission in Crohn's disease, with 92.4% of patients maintaining clinical remission and reduced hospitalizations compared to placebo.
LLYFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

Merck Seeks to Expand RSV Antibody Approval Following Positive Phase 3 Trial Results

Merck's RSV antibody Enflonsia shows positive Phase 3 results, supporting FDA expansion plans to protect more at-risk infants from respiratory syncytial virus infection.
MRKGSKmonoclonal antibodyFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Inventiva

Inventiva Reports €99.3M Cash Position Following $172.5M Capital Raise

Inventiva raises $172.5M, boosting cash position to €99.3M and extending runway through mid-2027 to fund MASH therapy development.
IVAcash positionfinancing